Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer
Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans
Vincent Chung, Alex Spira, Anna Pavlick, David Sommerhalder, Brett Hall, Vinny Hayreh, Jan de Jong, Jason Funt, Sarah Kolitz, Praveen Nair, Peter King, Jenny Zhang, Jason Kim, Amy Yamamura, Benjamin…
In a poster titled, “Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models,” IMM-1-104, gemcitabine (GEM), nab-paclitaxel (PAC), and 5-fluorouracil (5-FU) were evaluated in tumor…
